CaDAnCe-304
CaDAnCe-304 is the first phase 3 of a protein degrader in leukaemia, pitting BTK destruction against the best available BTK inhibitor.
Open-label, ~500 patients randomised 1:1 to BGB-16673 200 mg daily or pirtobrutinib 200 mg daily; primary endpoint PFS by IRC. Follows CaDAnCe-101 phase 1 (ORR 86% in 66 patients, EHA 2026). Enrolling 2025-27.
Pages like this
not linked directly; found by shared links- TrialBRUIN CLL-321
Shares Pirtobrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia, Acquired resistance to every therapy.
- TrialRESONATE
Shares BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
- Key paperZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors
Shares Pirtobrutinib, BTK (Bruton tyrosine kinase), Acquired resistance to every therapy.
- TrialALPINE
Shares BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
- TrialBELLWAVE-011
Shares BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
- TermRichter transformation
- ProductNemtabrutinib
Shares BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
- TrialELEVATE-TN
Shares BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.